These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36069771)

  • 1. Rates and types of urine drug screen false negative results compared with confirmatory toxicology testing in major trauma patients.
    Weiss ST; Veach LJ; McGill W; Brent J
    Clin Toxicol (Phila); 2022 Oct; 60(10):1122-1129. PubMed ID: 36069771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of urine drug screen utility at autopsy to predict laboratory postmortem blood toxicology.
    Arndt C; Huestis MA; Jarvis HC; Gray TR
    J Forensic Sci; 2024 Sep; 69(5):1815-1825. PubMed ID: 38898613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are point-of-care urine drug testing devices suitable for antenatal drug screening? A study verifying the Alere® Drug Screen Test Cup for the detection of six classes of drug in a pregnant population.
    Dale RC; Ford LT; Street C
    Ann Clin Biochem; 2021 May; 58(3):166-173. PubMed ID: 33435699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High on drugs: Multi-institutional pilot study examining the effects of substance use on acute pain management.
    Salottolo K; Peck L; Carrick M; Tanner A; Madayag R; McGuire E; Bar-Or D
    Injury; 2019 May; 50(5):1058-1063. PubMed ID: 30642622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine toxicology screening by liquid chromatography time-of-flight mass spectrometry in a quaternary hospital setting.
    Pope JD; Black MJ; Drummer OH; Schneider HG
    Clin Biochem; 2021 Sep; 95():66-72. PubMed ID: 33989561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Fluid and Drug Impairment: Pairing Toxicology with Drug Recognition Expert Observations.
    Truver MT; Palmquist KB; Swortwood MJ
    J Anal Toxicol; 2019 Sep; 43(8):637-643. PubMed ID: 31504595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use.
    Gryczynski J; Schwartz RP; Mitchell SG; O'Grady KE; Ondersma SJ
    Drug Alcohol Depend; 2014 Aug; 141():44-50. PubMed ID: 24932945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of psychoactive substances in truck drivers in the Nord-Pas-de-Calais region (France).
    Labat L; Fontaine B; Delzenne C; Doublet A; Marek MC; Tellier D; Tonneau M; Lhermitte M; Frimat P
    Forensic Sci Int; 2008 Jan; 174(2-3):90-4. PubMed ID: 17418990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in post-mortem whole blood.
    Pelletti G; Rossi F; Garagnani M; Barone R; Roffi R; Fais P; Pelotti S
    Forensic Sci Int; 2020 Jul; 312():110291. PubMed ID: 32353744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Monitoring of Psychoactive Substances in Psychiatric Patients Using Liquid Chromatography-High-Resolution Mass Spectrometry: A Key Tool for Treatment Planning and Understanding Consumption Patterns in Rome, Italy.
    La Maida N; Di Giorgi A; Pichini S; Pellegrini M; Di Trana A; Elmo MG; Polselli GM; Casella P; Di Stefano A; Ducci G
    Ther Drug Monit; 2024 Apr; 46(2):203-209. PubMed ID: 38018870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesia and Sedation Requirements in Mechanically Ventilated Trauma Patients With Acute, Preinjury Use of Cocaine and/or Amphetamines.
    Kram B; Kram SJ; Sharpe ML; James ML; Kuchibhatla M; Shapiro ML
    Anesth Analg; 2017 Mar; 124(3):782-788. PubMed ID: 28098590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal Urine Drug Screening with Rapid Confirmation upon Admission to Labor and Delivery.
    Haizler-Cohen L; Collins A; Kaplan DM; Giri P; Davidov A; Blau J; Fruhman G
    Am J Perinatol; 2024 Aug; 41(11):1512-1520. PubMed ID: 37369238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of New Psychoactive Substances (NPS) and conventional drugs of abuse (DOA) in high risk populations from Paris (France) and its suburbs: A cross sectional study by hair testing (2012-2017).
    Larabi IA; Fabresse N; Etting I; Nadour L; Pfau G; Raphalen JH; Philippe P; Edel Y; Alvarez JC
    Drug Alcohol Depend; 2019 Nov; 204():107508. PubMed ID: 31670189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commonly prescribed medications and potential false-positive urine drug screens.
    Brahm NC; Yeager LL; Fox MD; Farmer KC; Palmer TA
    Am J Health Syst Pharm; 2010 Aug; 67(16):1344-50. PubMed ID: 20689123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS.
    Farley M; Tran H; Towler S; Gevorkyan J; Pearring S; Rodda LN
    J Anal Toxicol; 2022 Jul; 46(6):658-669. PubMed ID: 34159389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between drug screening by immunoassay and ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry in post-mortem urine.
    Sundström M; Pelander A; Ojanperä I
    Drug Test Anal; 2015 May; 7(5):420-7. PubMed ID: 24953563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Urine Drug Screening on No Shows and Dropouts among Chronic Pain Patients: A Propensity-Matched Cohort Study.
    Krishnamurthy P; Ranganathan G; Williams C; Doulatram G
    Pain Physician; 2016 Feb; 19(2):89-100. PubMed ID: 26815253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.